Exploratory Study on Efficacy and Safety of Minocycline-Based Dual Therapy for Helicobacter pylori Eradication
Pathogens · 2025
DOI: 10.3390/pathogens14111121 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Pathogens, 2025. Verfasst von Wen Gao und 7 weiteren Autor:innen. Beteiligte Einrichtung: GI Department, Peking University First Hospital, Beijing 100034, China. Hauptthemen laut MEDLINE: Helicobacter Infections, Helicobacter pylori, Minocycline, Anti-Bacterial Agents. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National High Level Hospital Clinical Research Funding (Youth Clinical Research Project of Peking University First Hospital), Beijing Natural Science funding.
Abstract (Originalsprache)
Background & Aims: This study aimed to evaluate the feasibility of vonoprazan–minocycline (VM) dual therapy for Helicobacter pylori infection.
Methods
In this open-label RCT, 120 H. pylori-infected patients (60 treatment-naïve and 60 treatment-failure cases) were randomized to receive vonoprazan–amoxicillin dual therapy (VA: vonoprazan 20 mg b.i.d. + amoxicillin 1.0 g t.i.d., control group) or VM dual therapy (vonoprazan 20 mg b.i.d. + minocycline 100 mg b.i.d., test group) for 14 days. The primary outcome was eradication rates. Secondary outcomes included adverse effects (AEs).
Results
As first-line treatment, eradication rates were 96.7% (VA) vs. 90.0% (VM) in intention-to-treat (ITT) analysis (p = 0.30) and 96.7% (VA) vs. 96.4% (VM) in per-protocol (PP) analysis (p = 0.96). For rescue treatment, eradication rates were 86.7% (VA) vs. 76.7% (VM) in ITT (p = 0.32) and 89.7% (VA) vs. 79.3% (VM) in PP (p = 0.28). Overall eradication rates were 91.7% (VA) vs. 83.3% (VM) in ITT (p = 0.17) and 93.2% (VA) vs. 87.7% (VM) in PP (p = 0.31). VM had a higher incidence of AEs than VA (30.0% vs. 10.0%, p = 0.006), with dizziness being the most common (18.3%).
Conclusions
VM dual therapy was shown to be an effective and safe treatment option, demonstrating comparable eradication rates to VA dual therapy. While VM had a slightly higher incidence of AEs, they were generally mild and manageable. VM remained a valuable alternative for patients with penicillin allergies or amoxicillin resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- GI Department, Peking University First Hospital, Beijing 100034, China.
- School of Medicine, Tsinghua University, Beijing 100084, China.
- F. Widjaja Inflammatory Bowel Disease Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
ORCID-Profile: Wen Gao, Jingwen Li, Hong Cheng
Förderung
- National High Level Hospital Clinical Research Funding (Youth Clinical Research Project of Peking University First Hospital)
- Beijing Natural Science funding
Zitieren
APA
Gao, W., Li, J., Tian, Y., Ge, C., Wang, C., Liu, J., Li, Y., & Cheng, H. (2025). Exploratory Study on Efficacy and Safety of Minocycline-Based Dual Therapy for Helicobacter pylori Eradication. Pathogens. https://doi.org/10.3390/pathogens14111121
Vancouver
Gao W, Li J, Tian Y, Ge C, Wang C, Liu J, et al. Exploratory Study on Efficacy and Safety of Minocycline-Based Dual Therapy for Helicobacter pylori Eradication. Pathogens. 2025. doi:10.3390/pathogens14111121
BibTeX
@article{Gao2025,
author = {Gao, Wen and Li, Jingwen and Tian, Yuling and Ge, Chaoyi and Wang, Chi and Liu, Jianxiang and Li, Yixuan and Cheng, Hong},
title = {Exploratory Study on Efficacy and Safety of Minocycline-Based Dual Therapy for Helicobacter pylori Eradication},
journal = {Pathogens},
year = {2025},
doi = {10.3390/pathogens14111121}
}
EUVIMED